Tags

Type your tag names separated by a space and hit enter

[Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Farm Hosp. 2012 Jan-Feb; 36(1):11-5.FH

Abstract

OBJECTIVE

Cinacalcet is a calcimimetic agent, recommended for treating refractory secondary hyperparathyroidism in patients undergoing dialysis. The aim of this study was to evaluate the efficacy and safety of cinacalcet, comparing patients with baseline iPTH > 300 pg/ml with those with iPTH < 300 pg/ml.

METHOD

Observational retrospective study of patients being treated with cinacalcet 30 mg/day from January 2008 to January 2009. We studied 26 patients, 15 with iPTH > 300 pg/ml and 11 with iPTH < 300 pg/ml. The primary efficacy outcome was that there was a reduction between baseline and final iPTH (4 month). The secondary efficacy outcome were the reduction between basal and final calcium, phosphorus, Ca x P, and the percentage of patients with an iPTH decrease > 30%. The safety was evaluated based on the most frequent adverse effects and the levels of serum calcium < 8.6 mg/dl.

RESULTS

Patients with initial iPTH > 300 had significant differences before and after cinacalcet treatment in iPTH (563.49+286.88 pg/ml vs 315.15+201.948 pg/ml; P=.017) and serum calcium (9.1+1.77 mg/dl vs 8.15+1.2mg/dl; P=.02). There were no significant differences in patients with initial iPTH < 300 pg/ml. A decrease greater than 30% from baseline iPTH was observed in 60% of patients with baseline iPTH > 300 pg/ml, and only in 27.3% of those with basal iPTH < 300 pg/ml (P=.098). Patients did not show gastric intolerance.

CONCLUSIONS

Cinacalcet is an effective and safe drug for controlling secondary hyperparathyroidism in dialysis, mainly when it is used in patients with baseline iPTH > 300 pg/ml.

Authors+Show Affiliations

Departamento de Farmacia, Hospital Mateu Orfila, Maó-Menorca, España. gabriel.mercadal@hgmo.esNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

spa

PubMed ID

21514862

Citation

Mercadal Orfila, G, and I Blasco Mascaró. "[Retrospective Assessment of Effective and Safety of Cinacalcet for the Treatment of Secondary Hyperparathyroidism Depending On Basal iPTH Level]." Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria, vol. 36, no. 1, 2012, pp. 11-5.
Mercadal Orfila G, Blasco Mascaró I. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level]. Farm Hosp. 2012;36(1):11-5.
Mercadal Orfila, G., & Blasco Mascaró, I. (2012). [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level]. Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria, 36(1), 11-5. https://doi.org/10.1016/j.farma.2010.10.008
Mercadal Orfila G, Blasco Mascaró I. [Retrospective Assessment of Effective and Safety of Cinacalcet for the Treatment of Secondary Hyperparathyroidism Depending On Basal iPTH Level]. Farm Hosp. 2012 Jan-Feb;36(1):11-5. PubMed PMID: 21514862.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level]. AU - Mercadal Orfila,G, AU - Blasco Mascaró,I, Y1 - 2011/04/22/ PY - 2010/07/02/received PY - 2010/10/15/revised PY - 2010/10/25/accepted PY - 2011/4/26/entrez PY - 2011/4/26/pubmed PY - 2012/7/12/medline SP - 11 EP - 5 JF - Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria JO - Farm Hosp VL - 36 IS - 1 N2 - OBJECTIVE: Cinacalcet is a calcimimetic agent, recommended for treating refractory secondary hyperparathyroidism in patients undergoing dialysis. The aim of this study was to evaluate the efficacy and safety of cinacalcet, comparing patients with baseline iPTH > 300 pg/ml with those with iPTH < 300 pg/ml. METHOD: Observational retrospective study of patients being treated with cinacalcet 30 mg/day from January 2008 to January 2009. We studied 26 patients, 15 with iPTH > 300 pg/ml and 11 with iPTH < 300 pg/ml. The primary efficacy outcome was that there was a reduction between baseline and final iPTH (4 month). The secondary efficacy outcome were the reduction between basal and final calcium, phosphorus, Ca x P, and the percentage of patients with an iPTH decrease > 30%. The safety was evaluated based on the most frequent adverse effects and the levels of serum calcium < 8.6 mg/dl. RESULTS: Patients with initial iPTH > 300 had significant differences before and after cinacalcet treatment in iPTH (563.49+286.88 pg/ml vs 315.15+201.948 pg/ml; P=.017) and serum calcium (9.1+1.77 mg/dl vs 8.15+1.2mg/dl; P=.02). There were no significant differences in patients with initial iPTH < 300 pg/ml. A decrease greater than 30% from baseline iPTH was observed in 60% of patients with baseline iPTH > 300 pg/ml, and only in 27.3% of those with basal iPTH < 300 pg/ml (P=.098). Patients did not show gastric intolerance. CONCLUSIONS: Cinacalcet is an effective and safe drug for controlling secondary hyperparathyroidism in dialysis, mainly when it is used in patients with baseline iPTH > 300 pg/ml. SN - 2171-8695 UR - https://wwww.unboundmedicine.com/medline/citation/21514862/[Retrospective_assessment_of_effective_and_safety_of_cinacalcet_for_the_treatment_of_secondary_hyperparathyroidism_depending_on_basal_iPTH_level]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1130-6343(11)00077-8 DB - PRIME DP - Unbound Medicine ER -